https://european-biotechnology.com/wp-content/uploads/2024/04/20190715-compound-library.jpg5741020Uta Mommert/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngUta Mommert2019-07-15 10:58:002019-07-15 10:58:00Boehringer snaps up cancer vaccine developer
Healx, a Cambridge, UK, technology company developing treatments for rare diseases, today announces the appointment of Dr Neil Thompson, PhD, as Chief Scientific Officer (CSO).
/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png00Michael Kuhrt/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngMichael Kuhrt2019-07-11 13:54:002019-07-11 13:54:00Neil Thompson appointed CSO of Healx
Immatics Biotechnologies GmbH, a clinical-stage biopharmaceutical Company active in the discovery and development of T-cell redirecting cancer immunotherapies, today announced that Harpreet Singh has been appointed the Company’s Chief Executive Officer (CEO).
/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png00Michael Kuhrt/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngMichael Kuhrt2019-07-09 13:44:002019-07-09 13:44:00Harpreet Singh becomes CEO of Immatics
It is one of the largest single private funding rounds a biotech company in Europe has ever pulled off. German biotech BioNTech managed to raise US$325m (€290m) in an upsized Series B round to boost its immuno-oncology pipeline.
Biophytis has priced its IPO on Nasdaq Paris. The company aims to raise up to €10.8m to advance its lead drug candidate under development for the treatment of neuromuscular diseases.
German biotech group Evotec has once more launched a spin-off: Breakpoint Therapeutics GmbH is focusing on treating cancer patients by targeting DNA damage responses.
/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png00Uta Mommert/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngUta Mommert2019-07-08 06:58:002019-07-08 06:58:00€30m for Evotec cancer spin-out
A new collaboration aims to the urgent fight against antimicrobial resistant bacteria. Lyon-headquartered biotech Nosopharm has teamed up with German drug discovery company Evotec SE to develop a novel antibiotics class.
https://european-biotechnology.com/wp-content/uploads/2024/04/Cellectis-CAR_T.jpg8001200Uta Mommert/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngUta Mommert2019-07-05 06:58:002019-07-05 06:58:00Partnership in pursuit of new antibiotics class
Zelluna Immunotherapy, a biotechnology company specializing in T-cell receptor (TCR) immunotherapies, announced the appointment of Jens-Peter Marschner as chief medical officer (CMO) at the end of June.
Boehringer snaps up cancer vaccine developer
Latest NewsGerman pharma major Boehringer Ingelheim has taken over Swiss cancer immunotherapy player AMAL Therapeutics.
€28.5m for microalgae expert Microphyt
Latest NewsFrench microalgae specialist Microphyt has raised €28.5m to develop its microalgae portfolio for nutrition and cosmetics.
Neil Thompson appointed CSO of Healx
AppointmentsHealx, a Cambridge, UK, technology company developing treatments for rare diseases, today announces the appointment of Dr Neil Thompson, PhD, as Chief Scientific Officer (CSO).
€8m for universal flu vaccine
Latest NewsFrench biotech Osivax has raised €8m to fast-track development of its lead flu vaccine candidate – and branch out to Belgium.
Harpreet Singh becomes CEO of Immatics
AppointmentsImmatics Biotechnologies GmbH, a clinical-stage biopharmaceutical Company active in the discovery and development of T-cell redirecting cancer immunotherapies, today announced that Harpreet Singh has been appointed the Company’s Chief Executive Officer (CEO).
BioNTech pulls in massive €290m financing
Latest NewsIt is one of the largest single private funding rounds a biotech company in Europe has ever pulled off. German biotech BioNTech managed to raise US$325m (€290m) in an upsized Series B round to boost its immuno-oncology pipeline.
Biophytis launches €9m Nasdaq IPO
Latest NewsBiophytis has priced its IPO on Nasdaq Paris. The company aims to raise up to €10.8m to advance its lead drug candidate under development for the treatment of neuromuscular diseases.
€30m for Evotec cancer spin-out
Latest NewsGerman biotech group Evotec has once more launched a spin-off: Breakpoint Therapeutics GmbH is focusing on treating cancer patients by targeting DNA damage responses.
Partnership in pursuit of new antibiotics class
Latest NewsA new collaboration aims to the urgent fight against antimicrobial resistant bacteria. Lyon-headquartered biotech Nosopharm has teamed up with German drug discovery company Evotec SE to develop a novel antibiotics class.
Jens-Peter Marschner joins Zelluna
AppointmentsZelluna Immunotherapy, a biotechnology company specializing in T-cell receptor (TCR) immunotherapies, announced the appointment of Jens-Peter Marschner as chief medical officer (CMO) at the end of June.